Literature DB >> 9621463

Negative-strand RNA viruses: applications to biotechnology.

A García-Sastre1.   

Abstract

The establishment of reverse-genetics techniques to manipulate the genome of negative-strand RNA viruses has contributed enormously to a better understanding of the replication mechanisms and pathogenicity of this group of viruses. The generation of recombinant viruses bearing specific mutations in the coding and noncoding regions of their genomic RNAs now allows the functions in the replicative cycle of specific RNA regions and protein domains of these viruses to be studied. In addition, recombinant negative-strand RNA viruses can now be designed to have specific properties that make them attractive biotechnological tools.

Mesh:

Substances:

Year:  1998        PMID: 9621463     DOI: 10.1016/s0167-7799(98)01192-5

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  11 in total

1.  NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.

Authors:  K J Lee; I S Novella; M N Teng; M B Oldstone; J C de La Torre
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 3.  RNA virus vectors: where are we and where do we need to go?

Authors:  P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

4.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5.

Authors:  P M Gray; G D Parks; M A Alexander-Miller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 6.  Plasmid-only rescue of influenza A virus vaccine candidates.

Authors:  J H Schickli; A Flandorfer; T Nakaya; L Martinez-Sobrido; A García-Sastre; P Palese
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

7.  Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells.

Authors:  Sang Heui Seo; Robert G Webster
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Rescue of influenza A virus from recombinant DNA.

Authors:  E Fodor; L Devenish; O G Engelhardt; P Palese; G G Brownlee; A García-Sastre
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Richard Cadagan; Dmitriy Zamarin; Irina Petrushina; Nina Movsesyan; Luis Martinez-Sobrido; Randy A Albrecht; Adolfo García-Sastre; Michael G Agadjanyan
Journal:  J Transl Med       Date:  2011-08-01       Impact factor: 5.531

Review 10.  Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.